Abstract:Background: Intratympanic injections of glucocorticoids have become increasingly common in the treatment of idiopathic sudden sensorineural hearing loss (ISSHL). However, due to their fast elimination, sustained applications have been suggested for local drug delivery to the inner ear. Materials and methods: The study is based on a retrospective chart review of patients treated for ISSHL at a single tertiary (university) referral center. We included patients who were treated with a solid, biodegradable, poly(D,L-lactic-co-glycolic acid) (PLGA)-based drug delivery system providing sustained delivery of dexamethasone extracochlear into the round window niche ( n = 15) or intracochlear into scala tympani ( n = 2) for tertiary therapy of ISSHL in patients without serviceable hearing after primary systemic and secondary intratympanic glucocorticoid therapy. We evaluated the feasibility and safety through clinical evaluation, histological examination, and functional tests [pure-tone threshold (PTA), word recognition scores (WRS)]. Results: With adequate surgical preparation of the round window niche, implantation was feasible in all patients. Histologic examination of the material in the round window niche showed signs of resorption without relevant inflammation or foreign body reaction to the implant. In patients where the basal part of scala tympani was assessable during later cochlear implantation, no pathological findings were found. In the patients with extracochlear application, average preoperative PTA was 84.7 dB HL (SD: 20.0) and 76.7 dB HL (SD: 16.7) at follow-up ( p = 0.08). The preoperative average maximum WRS was 14.6% (SD: 17.9) and 39.3% (SD: 30.7) at follow-up ( p = 0.11). Six patients (40%), however, reached serviceable hearing. The two patients with intracochlear application did not improve. Conclusion: The extracochlear application of the controlled release system in the round window niche and – based on limited observations - intracochlear implantation into scala tympani appears feasible and safe. Due to the uncontrolled study design, conclusions about the efficacy of the treatment are limited. These observations, however, may encourage the initiation of prospective controlled studies using biodegradable controlled release implants as drug delivery systems for the treatment of inner ear diseases.

Biopolymer Lipid Hybrid Microcarrier for Transmembrane Inner Ear Delivery of Dexamethasone

Hydrogel Matrix Containing Microcarriers for Dexamethasone Delivery to Protect Against Cisplatin-Induced Hearing Loss

Silk-coated dexamethasone non-spherical microcrystals for local drug delivery to inner ear

Hyaluronic acid hydrogel sustains the delivery of dexamethasone across the round window membrane

Mastoid approach for local drug delivery to the inner ear for treating hearing loss

Inner ear delivery of dexamethasone using injectable silk-polyethylene glycol (PEG) hydrogel

Study on Dexamethasone Thermosensistivie in Situ Gel for Treating Deafness

Safety and audiological outcome in a case series of tertiary therapy of sudden hearing loss with a biodegradable drug delivery implant for controlled release of dexamethasone to the inner ear

Dexamethasone nanocrystals-embedded hydroxypropyl methylcellulose hydrogel increases cochlear delivery and attenuates hearing loss following intratympanic injection

Injectable Poloxamer Hydrogel Formulations for Intratympanic Delivery of Dexamethasone

A Single Dose of Dexamethasone Encapsulated in Polyethylene Glycol-Coated Polylactic Acid Nanoparticles Attenuates Cisplatin-Induced Hearing Loss Following Round Window Membrane Administration.

Programmable NIR Responsive Nanocomposite Enables Noninvasive Intratympanic Delivery of Dexamethasone to Reverse Cisplatin Induced Hearing Loss.

β-Cyclodextrin and Oligoarginine Peptide-Based Dendrimer-Entrapped Gold Nanoparticles for Improving Drug Delivery to the Inner Ear

Hyaluronic acid liposomal gel sustains delivery of a corticoid to the inner ear

In Vitro Permeability of Round Window Membrane to Transforming Dexamethasone with Delivery Vehicles——a Dosage Estimation

A silk-based hydrogel containing dexamethasone and lipoic acid microcrystals for local delivery to the inner ear

Novel self-degradable prodrug blend thermogel for intratympanic drug delivery to treat inner ear diseases

Microfluidic Preparation of Gelatin Methacryloyl Microgels As Local Drug Delivery Vehicles for Hearing Loss Therapy.

Dexamethasone Loaded Nanoparticles Exert Protective Effects Against Cisplatin-induced Hearing Loss by Systemic Administration

PLA–PCL–PEG–PCL–PLA based micelles for improving the ocular permeability of dexamethasone: development, characterization, and in vitro evaluation

The Preparation of Dexamethasone Sodium Phosphate Multivesicular Liposomes Thermosensative Hydrogel and Its Impact on Noise-Induced Hearing Loss in the Guinea Pigs.